Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Corporations' use and misuse of evidence to influence health policy: a case study of sugar-sweetened beverage taxation.

Fooks GJ, Williams S, Box G, Sacks G.

Global Health. 2019 Sep 25;15(1):56. doi: 10.1186/s12992-019-0495-5.

2.

Solitary intraventricular Hodgkin lymphoma post-transplant lymphoproliferative disease (HL-PTLD): Case report.

Azriel A, Towner JE, Gaillard F, Box G, Rogers T, Morokoff A.

J Clin Neurosci. 2019 Aug 23. pii: S0967-5868(19)31141-5. doi: 10.1016/j.jocn.2019.08.053. [Epub ahead of print]

PMID:
31451379
3.

Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.

Wagner S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust AG, Matthews N, Eason K, Khan K, Starling N, Cunningham D, Sadanandam A, Isacke CM, Kirkin V, Valeri N, Whittaker SR.

Oncogene. 2019 Jul;38(28):5746. doi: 10.1038/s41388-019-0835-1.

PMID:
31147600
4.

Correction: In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors.

Sharp SY, Boxall K, Rowlands M, Prodromou C, Roe SM, Maloney A, Powers M, Clarke PA, Box G, Sanderson S, Patterson L, Matthews TP, Cheung KJ, Ball K, Hayes A, Raynaud F, Marais R, Pearl L, Eccles S, Aherne W, McDonald E, Workman P.

Cancer Res. 2019 Jan 1;79(1):287. doi: 10.1158/0008-5472.CAN-18-3578. No abstract available.

PMID:
30602624
5.

Solid non-enhancing cerebellar pilocytic astrocytoma case report.

Towner JE, Azriel A, Rogers T, Box G, Adamides AA, Drummond K.

J Clin Neurosci. 2019 Feb;60:155-157. doi: 10.1016/j.jocn.2018.10.062. Epub 2018 Oct 23.

PMID:
30366781
6.

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.

Wagner S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust AG, Matthews N, Eason K, Khan K, Starling N, Cunningham D, Sadanandam A, Isacke CM, Kirkin V, Valeri N, Whittaker SR.

Oncogene. 2019 Mar;38(10):1717-1733. doi: 10.1038/s41388-018-0554-z. Epub 2018 Oct 23. Erratum in: Oncogene. 2019 May 30;:.

7.

Holmium-YAG laser: impact of pulse energy and frequency on local fluid temperature in an in-vitro obstructed kidney calyx model.

Sourial MW, Ebel J, Francois N, Box GN, Knudsen BE.

J Biomed Opt. 2018 Oct;23(10):1-4. doi: 10.1117/1.JBO.23.10.105002.

8.

Supracostal access tubeless percutaneous nephrolithotomy: minimizing complications.

Sourial MW, Francois N, Box GN, Knudsen BE.

World J Urol. 2019 Jul;37(7):1429-1433. doi: 10.1007/s00345-018-2518-x. Epub 2018 Oct 9.

PMID:
30302593
9.

Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N2-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N8-neopentylpyrido[3,4- d]pyrimidine-2,8-diamine (BOS172722).

Woodward HL, Innocenti P, Cheung KJ, Hayes A, Roberts J, Henley AT, Faisal A, Mak GW, Box G, Westwood IM, Cronin N, Carter M, Valenti M, De Haven Brandon A, O'Fee L, Saville H, Schmitt J, Burke R, Broccatelli F, van Montfort RLM, Raynaud FI, Eccles SA, Linardopoulos S, Blagg J, Hoelder S.

J Med Chem. 2018 Sep 27;61(18):8226-8240. doi: 10.1021/acs.jmedchem.8b00690. Epub 2018 Sep 10.

10.

Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma.

Baker LCJ, Sikka A, Price JM, Boult JKR, Lepicard EY, Box G, Jamin Y, Spinks TJ, Kramer-Marek G, Leach MO, Eccles SA, Box C, Robinson SP.

Front Oncol. 2018 Jul 23;8:271. doi: 10.3389/fonc.2018.00271. eCollection 2018.

11.

Transesophageal Echocardiography Guidance for Robot-assisted Level III Inferior Vena Cava Tumor Thrombectomy: A Novel Approach to Intraoperative Care.

Essandoh M, Tang J, Essandoh G, Iyer MH, Kuhn J, Opat K, Mandoff VL, Box GN.

J Cardiothorac Vasc Anesth. 2018 Dec;32(6):2623-2627. doi: 10.1053/j.jvca.2018.05.017. Epub 2018 Jun 13. No abstract available.

PMID:
29908891
12.

Value of combining dynamic contrast enhanced ultrasound and optoacoustic tomography for hypoxia imaging.

Shah A, Bush N, Box G, Eccles S, Bamber J.

Photoacoustics. 2017 Sep 7;8:15-27. doi: 10.1016/j.pacs.2017.08.001. eCollection 2017 Dec.

13.

Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI.

Boult JKR, Box G, Vinci M, Perryman L, Eccles SA, Jones C, Robinson SP.

Neoplasia. 2017 Sep;19(9):684-694. doi: 10.1016/j.neo.2017.05.007. Epub 2017 Aug 4.

14.

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma.

Ang JE, Pal A, Asad YJ, Henley AT, Valenti M, Box G, de Haven Brandon A, Revell VL, Skene DJ, Venturi M, Rueger R, Meresse V, Eccles SA, de Bono JS, Kaye SB, Workman P, Banerji U, Raynaud FI.

Mol Cancer Ther. 2017 Oct;16(10):2315-2323. doi: 10.1158/1535-7163.MCT-16-0881. Epub 2017 Jun 21.

15.

Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy.

Faisal A, Mak GWY, Gurden MD, Xavier CPR, Anderhub SJ, Innocenti P, Westwood IM, Naud S, Hayes A, Box G, Valenti MR, De Haven Brandon AK, O'Fee L, Schmitt J, Woodward HL, Burke R, vanMontfort RLM, Blagg J, Raynaud FI, Eccles SA, Hoelder S, Linardopoulos S.

Br J Cancer. 2017 Apr 25;116(9):1166-1176. doi: 10.1038/bjc.2017.75. Epub 2017 Mar 23.

16.

Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases.

Clarke PA, Ortiz-Ruiz MJ, TePoele R, Adeniji-Popoola O, Box G, Court W, Czasch S, El Bawab S, Esdar C, Ewan K, Gowan S, De Haven Brandon A, Hewitt P, Hobbs SM, Kaufmann W, Mallinger A, Raynaud F, Roe T, Rohdich F, Schiemann K, Simon S, Schneider R, Valenti M, Weigt S, Blagg J, Blaukat A, Dale TC, Eccles SA, Hecht S, Urbahns K, Workman P, Wienke D.

Elife. 2016 Dec 9;5. pii: e20722. doi: 10.7554/eLife.20722.

17.

Investigating intracranial tumour growth patterns with multiparametric MRI incorporating Gd-DTPA and USPIO-enhanced imaging.

Boult JK, Borri M, Jury A, Popov S, Box G, Perryman L, Eccles SA, Jones C, Robinson SP.

NMR Biomed. 2016 Nov;29(11):1608-1617. doi: 10.1002/nbm.3594. Epub 2016 Sep 27.

18.

Perinephric Hematoma and Hemorrhagic Shock as a Rare Presentation for an Acutely Obstructive Ureteral Stone with Forniceal Rupture: A Case Report.

Petros FG, Zynger DL, Box GN, Shah KK.

J Endourol Case Rep. 2016 Apr 1;2(1):74-7. doi: 10.1089/cren.2016.0033. eCollection 2016.

19.

Understanding and responding to demand in English general practice.

Box G.

Br J Gen Pract. 2016 Sep;66(650):456-7. doi: 10.3399/bjgp16X686701. No abstract available.

20.

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

Osborne JD, Matthews TP, McHardy T, Proisy N, Cheung KM, Lainchbury M, Brown N, Walton MI, Eve PD, Boxall KJ, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Jamin Y, Robinson SP, Westwood IM, van Montfort RL, Leonard PM, Lamers MB, Reader JC, Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I.

J Med Chem. 2016 Jun 9;59(11):5221-37. doi: 10.1021/acs.jmedchem.5b01938. Epub 2016 May 23.

21.

Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach.

Innocenti P, Woodward HL, Solanki S, Naud S, Westwood IM, Cronin N, Hayes A, Roberts J, Henley AT, Baker R, Faisal A, Mak GW, Box G, Valenti M, De Haven Brandon A, O'Fee L, Saville H, Schmitt J, Matijssen B, Burke R, van Montfort RL, Raynaud FI, Eccles SA, Linardopoulos S, Blagg J, Hoelder S.

J Med Chem. 2016 Apr 28;59(8):3671-88. doi: 10.1021/acs.jmedchem.5b01811. Epub 2016 Apr 7.

22.

Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.

Ang JE, Pandher R, Ang JC, Asad YJ, Henley AT, Valenti M, Box G, de Haven Brandon A, Baird RD, Friedman L, Derynck M, Vanhaesebroeck B, Eccles SA, Kaye SB, Workman P, de Bono JS, Raynaud FI.

Mol Cancer Ther. 2016 Jun;15(6):1412-24. doi: 10.1158/1535-7163.MCT-15-0815. Epub 2016 Apr 5.

23.

Crowd-Sourced Assessment of Technical Skills for Validation of Basic Laparoscopic Urologic Skills Tasks.

Kowalewski TM, Comstock B, Sweet R, Schaffhausen C, Menhadji A, Averch T, Box G, Brand T, Ferrandino M, Kaouk J, Knudsen B, Landman J, Lee B, Schwartz BF, McDougall E, Lendvay TS.

J Urol. 2016 Jun;195(6):1859-65. doi: 10.1016/j.juro.2016.01.005. Epub 2016 Jan 14.

PMID:
26778711
24.

PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion.

Dart AE, Box GM, Court W, Gale ME, Brown JP, Pinder SE, Eccles SA, Wells CM.

J Cell Biol. 2015 Nov 23;211(4):863-79. doi: 10.1083/jcb.201501072.

25.

Validation of the AUA BLUS Tasks.

Kowalewski TM, Sweet R, Lendvay TS, Menhadji A, Averch T, Box G, Brand T, Ferrandino M, Kaouk J, Knudsen B, Landman J, Lee B, Schwartz BF, McDougall E.

J Urol. 2016 Apr;195(4 Pt 1):998-1005. doi: 10.1016/j.juro.2015.10.087. Epub 2015 Oct 23.

PMID:
26527514
26.

A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.

Dale T, Clarke PA, Esdar C, Waalboer D, Adeniji-Popoola O, Ortiz-Ruiz MJ, Mallinger A, Samant RS, Czodrowski P, Musil D, Schwarz D, Schneider K, Stubbs M, Ewan K, Fraser E, TePoele R, Court W, Box G, Valenti M, de Haven Brandon A, Gowan S, Rohdich F, Raynaud F, Schneider R, Poeschke O, Blaukat A, Workman P, Schiemann K, Eccles SA, Wienke D, Blagg J.

Nat Chem Biol. 2015 Dec;11(12):973-980. doi: 10.1038/nchembio.1952. Epub 2015 Oct 26.

27.

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.

Walton MI, Eve PD, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Boxall KJ, Tall M, Swales K, Matthews TP, McHardy T, Lainchbury M, Osborne J, Hunter JE, Perkins ND, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Collins I, Garrett MD.

Oncotarget. 2016 Jan 19;7(3):2329-42. doi: 10.18632/oncotarget.4919.

28.

Multi-Institutional Validation of an OSATS for the Assessment of Cystoscopic and Ureteroscopic Skills.

Argun OB, Chrouser K, Chauhan S, Monga M, Knudsen B, Box GN, Lee DI, Gettman MT, Poniatowski LH, Wang Q, Reihsen TE, Sweet RM.

J Urol. 2015 Oct;194(4):1098-105. doi: 10.1016/j.juro.2015.02.2959. Epub 2015 May 27.

PMID:
26025502
29.

Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.

Mallinger A, Crumpler S, Pichowicz M, Waalboer D, Stubbs M, Adeniji-Popoola O, Wood B, Smith E, Thai C, Henley AT, Georgi K, Court W, Hobbs S, Box G, Ortiz-Ruiz MJ, Valenti M, De Haven Brandon A, TePoele R, Leuthner B, Workman P, Aherne W, Poeschke O, Dale T, Wienke D, Esdar C, Rohdich F, Raynaud F, Clarke PA, Eccles SA, Stieber F, Schiemann K, Blagg J.

J Med Chem. 2015 Feb 26;58(4):1717-35. doi: 10.1021/jm501436m. Epub 2015 Feb 13.

30.

Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography.

Jamin Y, Boult JKR, Li J, Popov S, Garteiser P, Ulloa JL, Cummings C, Box G, Eccles SA, Jones C, Waterton JC, Bamber JC, Sinkus R, Robinson SP.

Cancer Res. 2015 Apr 1;75(7):1216-1224. doi: 10.1158/0008-5472.CAN-14-1997. Epub 2015 Feb 11.

31.

Magnetic resonance imaging of intramedullary spinal cord lesions: a pictorial review.

Watts J, Box GA, Galvin A, Van Tonder F, Trost N, Sutherland T.

J Med Imaging Radiat Oncol. 2014 Oct;58(5):569-81. doi: 10.1111/1754-9485.12202. Epub 2014 Jul 2. Review.

PMID:
24986469
32.

Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.

Graham TJ, Box G, Tunariu N, Crespo M, Spinks TJ, Miranda S, Attard G, de Bono J, Eccles SA, Davies FE, Robinson SP.

J Natl Cancer Inst. 2014 Apr;106(4):dju033. doi: 10.1093/jnci/dju033. Epub 2014 Mar 14.

PMID:
24634505
33.

Magnetic resonance imaging of meningiomas: a pictorial review.

Watts J, Box G, Galvin A, Brotchie P, Trost N, Sutherland T.

Insights Imaging. 2014 Feb;5(1):113-22. doi: 10.1007/s13244-013-0302-4. Epub 2014 Jan 8.

34.

A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.

Box C, Mendiola M, Gowan S, Box GM, Valenti M, Brandon Ade H, Al-Lazikani B, Rogers SJ, Wilkins A, Harrington KJ, Eccles SA.

Eur J Cancer. 2013 Jul;49(11):2512-21. doi: 10.1016/j.ejca.2013.03.011. Epub 2013 Apr 10.

PMID:
23582742
35.

Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.

Lainchbury M, Matthews TP, McHardy T, Boxall KJ, Walton MI, Eve PD, Hayes A, Valenti MR, de Haven Brandon AK, Box G, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Garrett MD, Collins I.

J Med Chem. 2012 Nov 26;55(22):10229-40. doi: 10.1021/jm3012933. Epub 2012 Oct 19.

36.

Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.

Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, Moore AS, Kosmopoulou M, Brown N, Sheldrake PW, Bush K, Henley A, Box G, Valenti M, de Haven Brandon A, Raynaud FI, Workman P, Eccles SA, Bayliss R, Linardopoulos S, Blagg J.

J Med Chem. 2012 Oct 25;55(20):8721-34. doi: 10.1021/jm300952s. Epub 2012 Oct 8.

37.

CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.

Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, Hallsworth A, Smith EL, Boxall KJ, Lainchbury M, Matthews TP, Jamin Y, Robinson SP, Aherne GW, Reader JC, Chesler L, Raynaud FI, Eccles SA, Collins I, Garrett MD.

Clin Cancer Res. 2012 Oct 15;18(20):5650-61. doi: 10.1158/1078-0432.CCR-12-1322. Epub 2012 Aug 28.

38.

Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.

Bielen A, Box G, Perryman L, Bjerke L, Popov S, Jamin Y, Jury A, Valenti M, Brandon Ade H, Martins V, Romanet V, Jeay S, Raynaud FI, Hofmann F, Robinson SP, Eccles SA, Jones C.

Proc Natl Acad Sci U S A. 2012 May 15;109(20):E1267-76. doi: 10.1073/pnas.1105034109. Epub 2012 Apr 23.

39.

Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.

Reader JC, Matthews TP, Klair S, Cheung KM, Scanlon J, Proisy N, Addison G, Ellard J, Piton N, Taylor S, Cherry M, Fisher M, Boxall K, Burns S, Walton MI, Westwood IM, Hayes A, Eve P, Valenti M, de Haven Brandon A, Box G, van Montfort RL, Williams DH, Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I.

J Med Chem. 2011 Dec 22;54(24):8328-42. doi: 10.1021/jm2007326. Epub 2011 Nov 23.

40.

Editorial commentary.

Box G.

Surg Laparosc Endosc Percutan Tech. 2011 Aug;21(4):297. doi: 10.1097/SLE.0b013e318225b8e6. No abstract available.

PMID:
21857485
41.

Simple experimental and spontaneous metastasis assays in mice.

Box GM, Eccles SA.

Methods Mol Biol. 2011;769:311-29. doi: 10.1007/978-1-61779-207-6_21.

PMID:
21748685
42.

Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.

Bielen A, Perryman L, Box GM, Valenti M, de Haven Brandon A, Martins V, Jury A, Popov S, Gowan S, Jeay S, Raynaud FI, Hofmann F, Hargrave D, Eccles SA, Jones C.

Mol Cancer Ther. 2011 Aug;10(8):1407-18. doi: 10.1158/1535-7163.MCT-11-0205. Epub 2011 Jun 9.

43.

Non-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts.

Walker-Samuel S, Boult JK, McPhail LD, Box G, Eccles SA, Robinson SP.

Int J Cancer. 2012 Mar 15;130(6):1284-93. doi: 10.1002/ijc.26112. Epub 2011 Aug 1.

44.

Laparoscopic partial nephrectomy: six degrees of haemostasis.

Louie MK, Deane LA, Kaplan AG, Lee HJ, Box GN, Abraham JB, Borin JF, Khan F, McDougall EM, Clayman RV.

BJU Int. 2011 May;107(9):1454-9. doi: 10.1111/j.1464-410X.2010.09651.x. Epub 2011 Jan 18.

45.

Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.

Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB, Brown R.

Mol Cancer Ther. 2011 Feb;10(2):325-35. doi: 10.1158/1535-7163.MCT-10-0788. Epub 2011 Jan 7.

46.

Where do we really stand with LESS and NOTES?

Gettman MT, White WM, Aron M, Autorino R, Averch T, Box G, Cadeddu JA, Canes D, Cherullo E, Desai MM, Frank I, Gill IS, Gupta M, Haber GP, Humphreys MR, Irwin BH, Kaouk JH, Kavoussi LR, Landman J, Liatsikos EN, Lima E, Ponsky LE, Rane A, Ribal M, Rabenhalt R, Rao P, Richstone L, Sawyer MD, Sotelo R, Stolzenburg JU, Tracy CR, Stein RJ; Endourological Society NOTES and LESS Working Group; European Society of Urotechnology NOTES and LESS Working Group.

Eur Urol. 2011 Feb;59(2):231-4. doi: 10.1016/j.eururo.2010.11.016. Epub 2010 Nov 21. No abstract available.

PMID:
21122977
47.

Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.

Moffat D, Patel S, Day F, Belfield A, Donald A, Rowlands M, Wibawa J, Brotherton D, Stimson L, Clark V, Owen J, Bawden L, Box G, Bone E, Mortenson P, Hardcastle A, van Meurs S, Eccles S, Raynaud F, Aherne W.

J Med Chem. 2010 Dec 23;53(24):8663-78. doi: 10.1021/jm101177s. Epub 2010 Nov 16.

PMID:
21080647
48.

Robotic instrument insulation failure: initial report of a potential source of patient injury.

Mues AC, Box GN, Abaza R.

Urology. 2011 Jan;77(1):104-7. doi: 10.1016/j.urology.2010.01.093. Epub 2010 Sep 16.

PMID:
20846712
49.

Bayesian estimation of changes in transverse relaxation rates.

Walker-Samuel S, Orton M, McPhail LD, Boult JK, Box G, Eccles SA, Robinson SP.

Magn Reson Med. 2010 Sep;64(3):914-21. doi: 10.1002/mrm.22478.

50.

Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.

Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, Wilsher NE, Martins V, Reynisson J, Atrash B, Faisal A, Urban F, Valenti M, de Haven Brandon A, Box G, Raynaud FI, Workman P, Eccles SA, Bayliss R, Blagg J, Linardopoulos S, McDonald E.

J Med Chem. 2010 Jul 22;53(14):5213-28. doi: 10.1021/jm100262j.

PMID:
20565112

Supplemental Content

Support Center